Business context and reporting period
Bioventus Inc. filed this Form 10-K for the fiscal year ended December 31, 2021; it reports full-year results, not a standalone 2021 fourth quarter. The company develops and sells minimally invasive medical treatments across Pain Treatments, Surgical Solutions and Restorative Therapies. Its U.S. and International segments generated 90% and 10% of 2021 sales, respectively.
2021 included the March acquisition of Bioness and the October acquisition of Misonix, as well as Bioventus’s February IPO. Acquisition contributions and recovery from COVID-19-affected 2020 activity materially affect year-over-year comparisons.
Financial performance and liquidity
Amounts below are in millions of dollars unless noted.
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Net sales | $430.9 | $321.2 | +34.2% |
| Gross profit / margin | $302.7 / 70.3% | $233.5 / 72.7% | Margin down 2.4 percentage points |
| Operating income / margin | $12.1 / 2.8% | $21.2 / 6.6% | Income down $9.2 |
| Net income from continuing operations | $9.6 | $14.7 | Down $5.1 |
| Adjusted EBITDA (non-GAAP) | $80.8 | $72.4 | +11.5% |
| Operating cash flow | $23.0 | $72.2 | Down $49.2 |
Consolidated net income was $9.6 million, while net income attributable to Bioventus Inc. was $19.4 million, reflecting $9.8 million of losses attributed to noncontrolling interests. Class A loss per share was $0.15 for the post-IPO period beginning February 16, 2021; it is not a full-year comparable per-share measure.
U.S. sales were $387.6 million, up 32.0%; International sales were $43.3 million, up 57.8%. Sales by vertical were Pain Treatments $221.6 million, Restorative Therapies $121.6 million and Surgical Solutions $87.7 million. Management attributed growth to acquisitions and higher volume as activity recovered from pandemic impacts, partly offset by lower prices under certain insurer contracts. Acquisitions contributed approximately $49.4 million of sales from their respective closing dates.
Gross margin declined partly because of acquired-product mix, acquisition-related amortization and supply-chain delays. SG&A rose 31.7% to $254.3 million, reflecting acquisitions, public-company costs and normalized spending versus 2020. R&D rose 70.0% to $19.0 million. Adjusted EBITDA increased despite lower U.S. segment Adjusted EBITDA; International segment Adjusted EBITDA increased to $10.1 million from $3.2 million.
Cash, cash equivalents and restricted cash totaled $99.2 million at year-end, including $43.9 million of cash and equivalents and $55.3 million of restricted cash. Investing cash outflow was $283.8 million, principally reflecting acquisitions; financing cash inflow was $273.4 million, including debt and IPO proceeds. Net debt principal outstanding was approximately $357.7 million, with a $50.0 million revolving facility and approximately $49.9 million of availability. The term loan matures in October 2026; the company reported compliance with its financial covenants at year-end. Management said existing cash, revolver capacity and expected operating cash flow should cover anticipated requirements for at least 12 months.
Material changes, outlook and risks
- Acquisitions and funding: Misonix consideration totaled $525.3 million, including cash, Bioventus shares, options and amounts used to settle debt and expenses. Bioness required $48.9 million upfront; contingent consideration had a year-end fair value of $15.5 million, with maximum potential earn-outs reduced to $50.0 million after a $15.0 million FDA milestone was deemed unlikely.
- CartiHeal commitment: Bioventus deposited $50.0 million into escrow and expected FDA approval of Agili-C in the first half of 2022. The proposed purchase of the remaining shares was approximately $314.9 million, inclusive of the escrow deposit, with up to $135.0 million of additional sales-milestone payments. Approval and closing were not assured.
- Pipeline and regulatory uncertainty: The FDA identified deficiencies in the EXOGEN metatarsal-fracture PMA supplement; the company was reanalyzing data and warned approval could be delayed or denied. MOTYS sales ceased in the U.S. after FDA enforcement discretion ended in May 2021; resumption requires BLA approval. Agili-C, MOTYS, PROcuff and expanded EXOGEN indications involve clinical and regulatory risks.
- COVID-19 and supply: Patient visits, elective procedures, supply-chain continuity and customer payments remained uncertain. The company cited single-source suppliers, component shortages and allograft availability as risks. HA products accounted for 51% of 2021 revenue, creating product concentration.
- Other unusual items: The company recorded $5.7 million of impairment on Harbor assets and $1.4 million on its Harbor investment after terminating the collaboration. It also reported a voluntary Class II recall of certain ultrasound-gel vials supplied with EXOGEN; replacement gel was sourced, and $126,000 remained reserved at year-end. A $3.6 million Medicare claims settlement was finalized in February 2021.
- Guidance: The filing does not provide a clear quantified 2022 revenue or earnings forecast. Management described growth strategies and expected R&D spending to rise to the mid-single digits as a percentage of sales, but results remain subject to acquisition integration, reimbursement, regulatory, pandemic and supply risks.
- Contingencies and governance: Litigation includes Misonix-related stockholder disclosure claims and a Bioness shareholder fee dispute; the filing says outcomes or potential losses were not clearly estimable for certain matters. The 85% Tax Receivable Agreement could require significant future cash payments when tax benefits are realized. Bioventus reported effective disclosure controls and internal control over financial reporting; acquired Bioness and Misonix were excluded from management’s internal-control assessment.
Investor verification priorities
- Separate organic growth from acquisition contributions and COVID-19 recovery; verify the sales and margin trends by segment and product vertical.
- Reconcile GAAP net income, noncontrolling-interest allocations, post-IPO loss per share and the non-GAAP Adjusted EBITDA adjustments.
- Assess cash generation and restricted-cash availability against debt service, CartiHeal funding, contingent payments and other contractual commitments.
- Track CartiHeal FDA review and purchase obligations, EXOGEN supplement progress, MOTYS development costs and other pipeline milestones.
- Monitor reimbursement and pricing exposure, especially HA products and the proposed FDA down-classification of bone growth stimulators.
- Review integration execution, supplier concentration, recall resolution, litigation developments and the potential cash impact of the Tax Receivable Agreement.